Similar articles

• Restoring confidence in the pharmaceutical industry.

  Bauchner H, Fontanarosa PB. Bauchner H, et al. JAMA. 2013 Feb 13;309(6):607-9. doi: 10.1001/jama.2013.58. JAMA. 2013. PMID: 23403686 No abstract available.
• Critics say FDA's off-label guidance allows marketing disguised as science.

  Mitka M. Mitka M. JAMA. 2008 Apr 16;299(15):1759-61. doi: 10.1001/jama.299.15.1759. JAMA. 2008. PMID: 18413865 No abstract available.
• [Beyond "data sharing"].

  Lamarca R, Herrera D. Lamarca R, et al. Med Clin (Barc). 2015 Jun 22;144(12):548-9. doi: 10.1016/j.medcli.2015.02.005. Epub 2015 Apr 2. Med Clin (Barc). 2015. PMID: 25843632 Spanish. No abstract available.
• Confidentiality laws and secrecy in medical research: improving public access to data on drug safety.

  Kesselheim AS, Mello MM. Kesselheim AS, et al. Health Aff (Millwood). 2007 Mar-Apr;26(2):483-91. doi: 10.1377/hlthaff.26.2.483. Health Aff (Millwood). 2007. PMID: 17339677 Review.
• Drug development: how academia, industry and authorities interact.

  Garattini S, Perico N. Garattini S, et al. Nat Rev Nephrol. 2014 Oct;10(10):602-10. doi: 10.1038/nrneph.2014.133. Epub 2014 Aug 5. Nat Rev Nephrol. 2014. PMID: 25092151 Review.